Physician profile
John Naus
NPI 1932328291
$164,191.78
in general payments reported to CMS, 2019-2025
36 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $2,756 · 2021: $21K · 2022: $20K · 2023: $31K · 2024: $23K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Travel and Lodging: $9,427 · Food and Beverage: $8,232 · Consulting Fee: $5,500 · Honoraria: $2,275 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,086.75 |
| Travel and Lodging | $9,426.74 |
| Food and Beverage | $8,231.92 |
| Consulting Fee | $5,500.00 |
| Honoraria | $2,275.00 |
| Education | $167.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51,784.55 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $29,294.70 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $26,401.48 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24,229.23 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $16,966.63 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $8,212.40 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $932.90 | 2019-2025 | Ingrezza |
| Corium, LLC | $694.57 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $677.84 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $549.87 | 2019-2024 | Rexulti |
| Validus Pharmaceuticals LLC | $517.21 | 2019-2024 | Equetro |
| Takeda Pharmaceuticals U.S.A., INC. | $481.42 | 2019-2025 | Trintellix |
| Alkermes, INC. | $392.82 | 2021-2025 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $388.75 | 2019-2021 | |
| Allergan, INC. | $363.44 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $310.25 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $296.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $283.85 | 2019-2025 | Spravato, Invega Sustenna |
| Tris Pharma INC | $245.41 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, Lp | $233.37 | 2019-2025 | Adzenys Xr-Odt, Metadate Cd |
| Jazz Pharmaceuticals INC. | $161.54 | 2019-2024 | Xywav |
| Ironshore Pharmaceuticals INC. | $140.51 | 2019-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $89.72 | 2024-2025 | Lumryz |
| Noven Therapeutics, LLC | $83.12 | 2020-2024 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $77.86 | 2019 | |
| Shire North American Group INC | $60.25 | 2019 | |
| Idorsia Pharmaceuticals US INC | $59.26 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $56.19 | 2019-2025 | Aplenzin, Wellbutrin |
| Vertical Pharmaceuticals, LLC | $40.72 | 2019-2020 | |
| Masimo Corporation | $35.72 | 2022 | |
| Merck Sharp & Dohme LLC | $31.33 | 2023 | Belsomra |
| Almatica Pharma LLC | $29.01 | 2023 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $28.04 | 2019 | |
| Harmony Biosciences LLC | $18.11 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2019 | |
| Eisai INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Naus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.